Evidence Grade A — Regulatory approved. 83 published studies. 19 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Zilucoplan (sold as Zilbrysq) is a self-injectable treatment for generalised myasthenia gravis — a condition where the immune system attacks the connections between nerves and muscles, causing fluctuating weakness that can affect breathing, swallowing, and movement. Its key advantage over existing treatments is that patients can inject it themselves at home daily, rather than needing hospital visits for intravenous infusions.
Zilucoplan is also known by these brand and alternate names:
83 published studies: 52 human, 0 animal, 4 in-vitro, 31 reviews
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection.
In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
In antibody-positive myasthenia gravis, immune antibodies against the acetylcholine receptor activate the complement system — a destructive cascade of immune proteins. The final step of this cascade creates a 'membrane attack complex' (MAC) that punches holes in the muscle cell membrane at the neuromuscular junction, destroying the receptor-rich folds that receive nerve signals. Zilucoplan blocks complement component C5, preventing both the formation of the MAC and the release of the inflammatory signal C5a, halting the destruction.
The RAISE trial showed statistically significant improvements in both daily activities and muscle strength scores compared to placebo, with benefits appearing within the first week. As a small synthetic peptide (approximately 40 times smaller than the antibody-based complement inhibitors eculizumab and ravulizumab), zilucoplan can be delivered as a subcutaneous injection rather than requiring IV infusions. As with all complement inhibitors, patients must be vaccinated against meningococcal bacteria at least two weeks before starting treatment, because the drug reduces the immune system's ability to fight these infections. Data are currently limited to 12 weeks, with no head-to-head comparisons against existing treatments (eculizumab, ravulizumab, or efgartigimod). The self-administration convenience is the primary differentiator in a field where existing treatments work well but require hospital-based infusions.
PeptideTrace tracks 19 registered clinical trials for Zilucoplan sourced from ClinicalTrials.gov.
Zilucoplan for Severe gMG Exacerbations
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
FDA ORIG 1
EMA Marketing Authorisation
FDA SUPPL 4
FDA SUPPL 1
FDA SUPPL 9
FDA SUPPL 8
Health Canada Market Authorisation
FDA SUPPL 13
Zilucoplan is a macrocyclic peptide C5 inhibitor, 15 amino acids (synthetic), MW ~3,500 Da. Incorporates non-natural amino acids and PEG linker. Identified via mRNA display (>10^12 variants). Binds distinct C5 epitope vs. eculizumab. Small size (~3.5 kDa vs. ~148 kDa) enables SC self-administration. SC 0.3 mg/kg daily. Half-life ~25.5 hours.
Binds complement C5 (~0.5 nM Kd), preventing cleavage by C5 convertases into C5a (anaphylatoxin) and C5b (initiates MAC). In MG, anti-AChR antibodies activate classical complement at neuromuscular junction, causing MAC destruction of postsynaptic folds. Zilucoplan prevents both C5a inflammation and MAC formation.
Marketed as Zilbrysq. Approved October 17, 2023. RAISE (Phase III; N=174): MG-ADL improvement -3.37 vs. -2.30 (difference -1.07, P=0.0260). QMG: -4.39 vs. -2.30 (P=0.0052). Response from Week 1. Indication: anti-AChR antibody-positive gMG in adults.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
Bortezomib is marketed as Velcade (approved May 2003) for multiple myeloma and mantle cell lymphoma. Generic versions are available. Originally given intravenously, subcutaneous injection is now preferred as it causes significantly less nerve damage. The VISTA trial established bortezomib-based combination therapy as standard for newly diagnosed myeloma patients ineligible for transplant, with median time to disease progression of 24 months versus 16.6 months with older chemotherapy. Peripheral neuropathy (numbness and tingling in hands and feet) is the main dose-limiting side effect, affecting up to 30% of patients. Bortezomib transformed myeloma from a disease with a median survival of approximately 3 years to one where many patients live a decade or more with sequential treatments.
Daptomycin is marketed as Cubicin (approved September 2003). It is indicated for complicated skin and soft tissue infections and S. aureus bloodstream infections including right-sided endocarditis. Administered as a once-daily intravenous infusion. A key limitation is that daptomycin cannot be used for pneumonia — lung surfactant inactivates the drug. In the bacteraemia trial, daptomycin was non-inferior to vancomycin with significantly lower rates of kidney problems (11% versus 26%). Creatine kinase (CK) levels must be monitored during treatment, as daptomycin can cause muscle toxicity. Generics became available after patent expiry, significantly reducing cost.
Comparisons
Evidence Reviews
Timelines
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
